Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 11/03/25
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public OfferingBusiness Wire • 10/30/25
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)Business Wire • 09/19/25
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)Business Wire • 09/04/25
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 08/12/25
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to BuyZacks Investment Research • 07/22/25
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocksProactive Investors • 06/18/25
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to TradeZacks Investment Research • 06/02/25
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial OfficerBusiness Wire • 05/27/25